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5INTRODUCTION
The microbes that surround us constantly invade our body, many of them through
respiratory airways, where mucosal surfaces form the first line of defence against
pathogenic bacteria. This challenge by pathogens is met by both nonspecific and
specific defence mechanisms of the immune system, both already  functioning locally
at mucosal surfaces. The specific immune system has a unique capability to recognise
a specific pathogen, target the defence against it, and recognise the same pathogen even
years later. This memory function has been described for both systemic and mucosal
immune responses.
Each pathogen has its own strategy to gain access into the human body, but also the
immune system has a specific strategy for the fight against each pathogen. It is therefore
essential to study the pathogenesis of each disease and the human defence mechanisms
against each pathogen,  in order to develop preventive and therapeutic means, e.g.,
vaccines, against the disease. Acute otitis media (AOM) is an example of an infection
restricted to mucosal membranes. It is common among small children; nearly all
children experience at least one AOM episode before the age of two years.
The most common causative bacterium of AOM is Streptococcus pneumoniae, the
pneumococcus (Pnc). An important virulence factor for the pneumococcus is the
polysaccharide (PS) capsule, which helps it to avoid  phagocytosis. Since the
pneumococci are encapsulated bacteria, it is essential for the immunological defence to
produce antibodies against the polysaccharide capsule in order to fight against the
pathogen. Pneumococcal PS vaccines, consisting of polysaccharides of different
serotypes of the pneumococcus, are immunogenic in the adult population, i.e., able to
induce antibody production against the capsular PS. However, these vaccines are able
to induce only poor, if any, antibody responses in infants and young children, who are
the most susceptible to pneumococcal diseases, partly because of the immaturity of their
immune system. The poor response to PS seen in small children is due to the T-
independent nature of these antigens, which means the PS vaccines are unable to induce
T-cell help for antibody production. However, coupling of the PS antigens to a protein
carrier turns them into T-dependent antigens, which are recognised by helper T-cells
that then stimulate antibody production by B-cells. Conjugate vaccines consisting of
pneumococcal PS coupled to different carrier proteins have already been shown to be
immunogenic in young children and infants.
Haemophilus influenzae type b (Hib) conjugate vaccines, and more recently also
pneumococcal conjugate vaccines, have been shown to reduce colonisation with the
respective bacteria in the nasopharynx, suggesting that parenteral immunisation can
induce protection at mucosal surfaces. Thus the pneumococcal conjugate vaccines can
be expected to prevent, in addition to serious invasive infection, mucosal infections
such as pneumococcal AOM and pneumonia.
6This thesis describes part of a larger series of studies, carried out to characterise the
immune responses related to AOM and to study the immunogenicity of the
pneumococcal conjugate vaccines. The focus of this work is on induction of mucosal
antibody responses, both those seen in AOM and those induced by parenterally
administered pneumococcal conjugate vaccines.
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1. Streptococcus pneumoniae 
Streptococcus pneumoniae (pneumococcus, Pnc) is a gram-positive, encapsulated,
facultatively anaerobic coccus, with a distinctive asymmetric ‘lancet’ shape. S.
pneumoniae was formerly known as Diplococcus, because it usually appears in pairs
and consequently was believed to belong to a genus separate from Sreptococcus. These
morphological characteristics help in identification of the bacteria. Three morphological
layers can be distinguished in the surface of Pnc: plasma membrane, cell wall, and
capsule. The peptidoglycan of the cell wall anchors the cell wall polysaccharide (CPS),
and also proteins, in addition to the capsular polysaccharide.
The  S. pneumoniae bacteria have a thick polysaccharide capsule that covers the inner
structure of the bacteria (Skov Sorensen et al. 1988). Some proteins, such as the
pneumococcal surface protein A (PspA), however, are exposed beyond the capsule
(Gray 1996). Based on its capacity to prevent phagocytosis (Wood and Smith 1949), the
capsule is established as a major virulence factor of pneumococci (Lee et al 1991),
enabling the pneumococci to survive and multiply in the host. The pneumococci  are
classified into 90 serotypes based on the antigenic variability of the capsule (Kauffman
et al 1960, Lund and Henrichsen 1978, Austrian et al 1985, Henrichsen 1995). Each
serotype can be identified by its reaction with type-specific antisera. This was first done
by the Quellung reaction (Neufeld 1902), in which the bacteria are mixed with antisera
and methylene blue, resulting in a swelling reaction that can be visualised in
microscope (Balows et al. 1991). More recently, counter-immunoelectrophoresis and
latex agglutination and coagglutination tests have also been used for serotyping
(Leinonen 1980, Trollfors 1983). The classification can be done according to two
nomenclatures, the American and the Danish (Kauffman et al. 1960), of which the
Danish nomenclature has been widely adopted since the early 1980's.
The cell wall of  S. pneumoniae  is responsible for the intense inflammatory reaction
that accompanies a pneumococcal infection (Tuomanen et al.1985 and 1987, Carlsen et
al. 1992). The cell-wall components peptidoglycan and teichoic acid are inflammatory
mediators as potent as the lipopolysaccharide (LPS) of some gram-negative bacteria. In
experimental meningitis, the peptidoglycan is shown to cause cerebral oedema and the
teichoic acid to generate increased intra-cranial pressure (Tuomanen et al. 1985). This
suggests that highly effective bactericidal antibiotics, such as beta-lactams, may in some
cases adversely affect the outcome of pneumococcal meningitis, because they lyse
pneumococci, which leads to release of cell-wall components (Bruyn et al. 1992). Thus,
the inflammatory reaction of the host is responsible for most of the symptoms of
pneumococcal disease, and it is suggested as being responsible for the high mortality
from pneumococcal infections (Musher 1992)
The surface of  S. pneumoniae is decorated with a family of choline-binding proteins
bound to the phosphorylcholine of the teichoic acid. The major cell-wall hydrolase (or
8major autolysin, LytA) was the first of these proteins characterised (Garcia et al. 1986).
It is responsible for the cleavage of peptidoglycan and thus indirectly mediates
inflammation and release of other non-exported virulence factors, such as pneumolysin
(Mitchell et al. 1997). A second choline-binding protein characterised, the
pneumococcal surface protein A (PspA) (Briles et al 1981), is an antigenically variable
surface protein present in all clinically important isolates (Briles et al 1989, Crain et al.
1990). It seems to be essential for full virulence and is shown to interfere with the blood
clearance, but its mechanisms of specific action remain unknown (McDaniel et al. 1987,
Briles et al.1988). In addition, other choline-binding proteins have been characterised
more recently (Rosenow et al. 1997). A different kind of surface protein has also been
identified , the pneumococcal surface adhesin protein (PsaA) (Russell et al. 1990). It is
common to all pneumococci and is highly conserved in the clinically notable serotypes
(Sampson et al. 1997). No role for PsaA has yet been determined, but it has been
hypothesized to be a permease (Crook et al 1998).
Pneumolysin is an intracellular protein released upon autolysis (Johnson 1977); it is
produced by virtually all Pnc isolates (Walker et al. 1987, Kanclerski and Mollby
1987). The pneumolysin can interfere with the host’s ability to attack the invading
pneumococci by multiple effects on the host’s immune system. It activates the classical
pathway of complement in the absence of antibodies (Paton et al. 1984). Pneumolysin
decreases the bactericidal activity and migration of neutrophils (Johnson et al. 1981,
Paton and Ferrante 1983) and inhibits lymphocyte proliferation and antibody production
in vitro (Ferrante et al. 1984). Furthermore, it inhibits the beating of the cilia of human
epithelial cells, and disrupts cultured epithelial cells from the respiratory tract and
pulmonal alveoli (Feldman et al. 1990, Rubins et al. 1993).
Several enzymes that are produced by Pnc (autolysin, hyaluronidase and glycosidases
such as neuraminidase) also enhance its virulence. The IgA1 protease produced by
pneumococcus may be an important enzyme. It is highly specific for human IgA and
can thus interfere with host defences at mucosal surfaces (Kilian et al. 1979, Male
1979). In addition, fab fragments generated by this protease retain their antigen-binding
capacity (Mallett et al. 1984, Mansa and Kilian 1986) and may protect the pneumococci
by inhibiting the binding of intact immunoglobulin, thus preventing the Fc-dependent
elimination of the opsonized pneumococci (Kilian et al. 1988, Kilian et al.1996).
Furthermore, indirect evidence of cleavage of IgG and IgM has been described
(Wikström et al. 1984).
2. Pneumococcus in the upper respiratory mucosa
2.1. Pathogenesis of pneumococcal disease
S. pneumoniae is a human pathogen which spreads from person to person by aerosols.
It is  carried in the nasopharynx without any apparent symptoms, which helps it to
persist in the human population. The infection begins with colonisation in the
nasopharynx by the bacteria. From there the bacteria can gain access to the lungs or
Eustachian tubes. If the bacteria enter the Eustachian tubes and start growing there, they
9trigger an inflammatory response that causes pain, fever, and earache. The bacteria may
also enter the bloodstream directly, although the mechanisms of entry and the
conditions that enable the translocation of the bacteria are unknown. Toxins secreted by
the bacteria and the products liberated after breakdown (cell-wall components,
pneumolysin) are suggested to play a role (Johnston 1991). The direct damage to
epithelial cells by hydrogen peroxidase and the effect of pneumolysin on ciliary beating
also facilitates the access of pneumococci into the bloodstream (Boulnois 1992).
Furthermore, the intense inflammatory response enhanced by these by-products or
concurrent viral infections may be important. Some experimental studies have
suggested that conversion to invasive disease may involve generation of local
inflammatory factors which change the number and type of receptors available by
activating human cells (Cundell et al. 1995, Tuomanen et al. 1997).
2. 2. Mucosal carriage
Asymptomatic carriage rates of  pneumococcus vary widely by age and population. In
Virginia, in the USA, carriage rates reported in the early 1970 were 38% in preschool
children, decreasing by age to 19% in the adult population (Hendley et al.1975). These
results are very similar to those reported back in 1939 by Heffron (see Hendley et al.
1975). The most frequently isolated serogroups were, 3, 4, 6, 7, 19, and 23.  The spread
of pneumococci is efficient within families, and in adults, carriage rates are clearly
affected by their exposure to young children at home (Hendley et al. 1975). Moreover,
carriage rates of pneumococci are reported to be higher in children with AOM or other
respiratory tract infections than in healthy children of the same age-group (Willard and
Hanssen 1957, Herva 1980, Luotonen 1982, Faden 1990, Takala et al. 1991, Aniansson
et al. 1992). Nasopharyngeal acquisition of Pnc in newborn infants is greatly affected
by living conditions. In Alabama, in the USA, nasopharyngeal carriage was observed
from the age of 4 days on, the mean age for acquisition being 10 months (Gray et al.
1980). By the age of two years, 96% of the children had carried Pnc at least once. In
Papua New Guinea, the reported carriage rate is already 100% by the age of three
months (Gratten et al. 1986). In comparison, a study in Sweden showed carriage rates
of 12% by the age of three months and 67% by the age of 18 months (Aniansson 1992).
2. 3. Acute otitis media
The middle ear cavity is normally dry and free of bacteria. It is connected to the
nasopharynx by the Eustachian tube, which equilibrate air pressure between the middle
ear and nasopharynx. However, its function is poorer in children than in adults
(Bylander 1980, Bylander and Tjernstöm 1983). In acute otitis media (AOM) the
colonising bacteria gain access into the middle ear cavity through the Eustachian tube.
The pathogenesis of AOM is considered to be related to the compromised middle-ear
ventilation secondary to Eustachian tube dysfunction, presence of pathogenic bacteria
in the nasopharynx, and biochemical and immunological host responses (Hendersson
and Giebink 1986). An upper respiratory tract infection is believed to result in
congestion and obstruction of the Eustachian tubes, leading to accumulation of fluid in
the middle ear cavity (Giebink 1989). Especially respiratory syncytical virus (RSV)
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epidemics have been shown to correlate with the occurrence of AOM (Ruuskanen et al.
1989), and RSV has been detected in both the nasopharynx and the middle ear of AOM
patients (Klein et al.1982, Sarkkinen et al.1985, Chonmaitree et al.1986, Arola et al.
1988, Heikkinen et al.1999). In addition to RSV, parainfluenza and influenza viruses
have frequently been detected in the middle ear of AOM patients: RSV in 74% of the
children with RSV infection, and parainfluenza in 52% and influenza in 42% of the
children infected with the respective viruses (Heikkinen et al.1999). Another study has
suggested that besides RSV epidemics, the rhino virus is the most common virus
detected in children with AOM (Arola et al.1990).
Based on bacterial cultures, Pnc is the predominant bacterial species in the middle ear
fluid (MEF) in AOM patients, isolated in 30 to 40% of the cases (Karma et al. 1987).
Haemophilus influenzae is the second most common isolate (10-20%), and
Branhamella catarrhalis the third.  Streptococcus pyogenes and Staphylococcus aureus
are less frequent findings (Karma et al. 1987). If antigen detection is added to the
diagnostic methods for AOM, Pnc has been implicated in nearly 60% of all AOM cases
(Luotonen et al. 1981). In the most recent study in Finland, Pnc was isolated less
frequently, in 26% of all AOM cases from which a MEF sample was obtained (Kilpi et
al. 1999).
The serotypes causing acute otitis media (AOM) have been shown to differ to some
extent from those causing invasive diseases (Klein 1981, Pedersen and Henrichsen
1983, Gray and Dillon 1986). However, the serotypes isolated from asymptomatic
carriers are the serotypes that most frequently cause AOM (Austrian et al.1977). The
Pnc serogroups most commonly involved in AOM are 19, 23, 6, and 14, in this order
(Karma et al. 1987, Kilpi et al. 1999). In most cases, the infection does not occur after
a prolonged carriage state, but arises from a recent acquisition of the pneumococcus
(Gray et al.1980). Therefore a prolonged carriage state might even be beneficial for the
host by preventing other, more virulent strains from colonising the nasopharynx and
thus limiting new acquisitions (Gray et Dillon 1986).
The incidence of AOM shows great variation between populations and studies. The
cumulative incidence of the first episode at 12 months of age ranged from 28%
(Pukander et al. 1982) to 45% (Sipilä et al.1987) in Finnish studies, but reached 62% in
studies from the USA (Teele et al.1989). The cumulative incidence at 24 months of age
was 71% in Finland (Alho et al. 1990), 36% in Sweden (Lundgren and Ingvarsson
1983) and 61% in the USA (Howie et al. 1975). According to these studies, the
incidence is highest in children aged from 6 to 12 months. The earlier in childhood the
first AOM episode occurs, the higher is the risk of recurrent episodes (Kaplan et al.
1973, Howie et al 1975, Teele et al. 1989).
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3. Host defence against pneumococcal disease
3. 1. Mucosal sites 
In healthy humans the mucosal barrier in the upper respiratory tract is the first line of
defence against pathogens invading the body via the airways. Intact mucosal
epithelium, mucous clearance, and the ciliated cells in the airways, together with
antibacterial proteins and peptides on the mucosal surfaces, prevent pathogens from
spreading from the nasopharynx into the surrounding tissues and lungs. In addition to
this ‘innate immunity’, the specific, antibody-mediated defence takes action already at
the mucosal surfaces, where IgA is the predominant immunoglobulin isotype. In
secretions, IgA occurs in its secretory form. Secretory IgA (S-IgA) is found in
polymeric forms, with a dimeric form dominating. Monomers of IgA are connected to
one another by the J-chain. The J-chain binds the complex to the secretory component
(SC). The membrane-bound form of the SC (polyimmunoglobulin receptor) on the
basolateral side of epithelial cells functions as the specific receptor for the polymeric J-
chain containing immunoglobulins. Binding of  IgA to SC mediates the specific
transport into secretions (Fig 1), stabilises the polymeric immunoglobulin, and protects
it against proteolytic enzymes (Russel et al. 1992). 
Figure 1. The selective transport of J chain containing polymeric IgA (pIgA) through
epithelial cells. The membrane-bound form of secretory component (SC) on the
basolateral side of epithelial cells functions as the receptor for polymeric IgA. The
interaction of transmembrane SC to pIgA mediates the specific transmigration of S-IgA
into secretions. The SC-pIgA complex is internalised in endoplasmic vesicles. These
vesicles fuse with the apical membrane, and S-IgA is released in external secretion.
(Modified from Kuhn and Krahenbuhl 1982, Trends Biochem Sci.)
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Inhibition of bacterial and viral adherence is an essential function for IgA in secretions.
In co-operation with innate defence factors, the S-IgA inhibits epithelial colonisation,
and decreases penetration of antigens through mucosal membranes. S-IgA also
neutralises viruses, bacterial toxins, and enzymes (Table 1). IgA appears in two
isotypes, IgA1 and IgA2, the distribution between them varying by mucosal site
(Delacroix et al. 1982). In the upper respiratory tract and upper gastrointestinal tract, the
IgA1 isotype is predominant, but the proportion of  IgA2 increases further along the
gastrointestinal tract. Only in the lower gastrointestinal tract is the majority of the IgA
of the IgA2 isotype (Mestecky and Russel 1986, Brandtzaeg et al. 1986, Kett et al.
1986).
Table 1.
Biological functions of  S-IgA
direct
Neutralisation of biologically active antigens
(viruses, toxins, enzymes)
Inhibition of microbial adherence
Inhibition of antigen penetration 
(immune exclusion)
indirect
Opsonisation for mucosal polymorphonuclears and macrophages
(promotion of phagocytosis)
Antibody-dependent cellular cytotoxicity
Enhancement of antibacterial humoral factors in secretions
(lactoferrin and peroxidase system)
Enhancement of monocyte and lymphocyte-dependent bactericidal activity
The B-cells responsible for local polymeric IgA production are mainly derived from
organized mucosa-associated lymphoid tissue (MALT). The components of MALT in
the upper respiratory tract form a structure called Waldeyer’s ring that includes the
palatine and pharyngeal tonsils (“adenoids”) (Fig 2). In the lower respiratory tract the
lymphatic tissue is referred to as the bronchus-associated lymphoid tissue (BALT).
Primed B-cells and T-cells from all inductive lymphoepithelial structures of the MALT
migrate via peripheral blood to exocrine tissues throughout the body (Gowans et al.
1964). The integrated mucosal immune system thus ensures that all mucous membranes
are furnished with a wide spectrum of secretory antibodies. However, accumulating
evidence suggests that regionalised homing mechanisms of activated cells do take place
(Brandtzaeg et al. 1999). Thus the cells stimulated at the lymphoid tissues of the upper
13
respiratory tract would preferentially home to the upper respiratory mucosa, a
hypothesis also supported by some experimental animal studies (Nadal et al. 1991). 
Figure 2.
Waldeyer’s tonsillar ring, consisting of an unpaired pharyngeal tonsil in the roof of the
pharynx, paired palatine tonsils and lingual tonsils scattered in the root of the tongue.
(Modified from Kahle et al. Color Atlas and Textbook of Human Anatomy).
Whether the middle ear mucosa is a part of the integrated ‘common’ mucosal system
still remains a matter of controversy (Kuper et al. 1992). Although there are few
lymphocytes and other immunocompetent cells in the normal middle ear mucosa,
antigen-specific IgA-forming cells can be induced in the middle ear mucosa during
otitis media (Watanabe et al. 1988). IgA precursors homing to the middle ear can be
induced in the adenoids and tonsils (Bernstein et al. 1988), but GALT or BALT can
also serve as a source for precursors of the cells homing to the middle ear (Watanabe et
al. 1988). However, the IgA-secreting cells are shown to be drawn to the middle ear in
a relatively nonspecific manner, instead of  homing by specific receptors  (Ryan et al.
1990). Thus, it is rather the inflammation of the middle ear mucosa that accelerates the
recruitment of the cells from the circulation (Kato et al.1994). Moreover, in children
with AOM, the IgA in the nasopharynx is locally produced and is secretory in nature,
whereas a significant proportion of IgA in the middle ear in the acute phase of AOM
infection seems to be derived from serum (Virolainen et al. 1995a, Virolainen et al.
1995b). Nevertheless, the presence of pathogen-specific S-IgA in the MEF as early as
at the onset of AOM seems to be beneficial for the resolution of the disease (Sloyer et
al.1974, Sloyer et al.1976, Karjalainen et al. 1990).
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In addition to polymeric IgA, pentameric IgM is likewise actively enriched in most
exocrine fluids and is associated with SC, whereas IgG mostly leaks into secretions
passively, although it may also be partially locally produced (Brandtzaeg et al. 1991,
Bouvet and Fischetti 1999). Furthermore, leakage of IgG into exocrine fluids is
enhanced by mucosal irritation. Although IgG is not considered a secretory
immunoglobulin, it may contribute to immune exclusion (Brandtzaeg et al. 1987) and
inhibit colonisation at mucosal sites (Kauppi et al. 1993). This can be seen especially in
the respiratory tract, where the IgG is less easily subjected to proteolytic degradation
than in the intestinal tract (Persson et al. 1998). On the other hand, by activating
complement, IgG may actually accelerate mucosal penetration of antigens and may thus
contribute to persistent immunopathology at the mucosal sites.
3. 2. Systemic sites 
If the bacteria succeed in spreading into the deeper organs, a concerted action of
antibodies, complement components, and phagocytic cells takes place (Gillespie 1989,
Bruyn et al. 1992, Watson et al. 1995). As the polysaccharide capsule is able to disturb
phagocytosis by preventing direct contact between phagocytes and pneumococcus, the
opsonisation of the bacteria by antibodies or by complement components is crucial for
phagocytosis (Johnston et al. 1981). If impairment in any of these functions appears,
such as complement or immunoglobulin deficiencies, it will readily predispose the host
to severe pneumococcal infections. The spleen has an essential role both in initiating
production of antibodies to pneumococcus and in the clearance of the opsonized
bacteria from the bloodstream (Wara 1981). The importance of the spleen as a filtration
organ that removes pneumococci from the bloodstream is seen in those with
splenectomies or splenic dysfunction. Such patients are particularly prone to rapid
progress of pneumococcal disease, especially septic bacteremia following pneumonia.
In the presence of anti-PS antibodies, the classical complement pathway is activated,
and with its essential assistance the pneumococcus is effectively cleared from the blood
by the liver and spleen (Brown et al. 1983, Holzer et al. 1984). However, phagocytosis
may also be mediated by innate immunity components such as lectins and other
carbohydrate-binding proteins in the liver and spleen of a non-immune host (Ofek and
Sharon 1988). Nevertheless, whether or not the opsonisation is antibody mediated, an
intact complement system is essential for the clearance of the bacteria (Brown et al
1983). Furthermore, the CPS and capsular PS of the pneumococcus (Winkelstein and
Thomaz 1978, Hostetter 1986) are able to activate the alternative complement pathway
that leads to production of opsonising complement components.
4. Antibody-mediated immunity to polysaccharide antigens
4. 1. Polysaccharides as antigens
Polysaccharide antigens differ from protein antigens in the manner in which they are
processed and presented (Stein 1992, Mond et al. 1995). The responsiveness of the
immune system to polysaccharide antigens develops late in ontogeny (Peltola et al.
1977, Parke et al. 1977, Käyhty et al. 1984), due to specific characteristics of
polysaccharides as antigens. Protein antigens are mostly T-cell-dependent (TD)
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antigens presented to T-cells by the major histocompatibility class II (MCH II)
molecules on antigen-presenting cells (APC). The B-cells specific for these TD antigens
require help for antibody production from stimulated T-cells. The PS antigens, by
contrast, are thymus-independent, or T-cell independent (TI) antigens. Two types of  TI
antigens exist. Type 1 TI antigens are bacterial products such as LPS that function as
mitogenic or polyclonal B-cell activators. The  TI-1 response is totally independent of
T-cell regulatory activity, and can be evoked in early infancy. Type 2 TI antigens are
mostly high-molecular weight polymers with repeated structures, such as bacterial
capsular polysaccharides (Mosier and Subbarao 1982) and virus surface capsids (Fehr
et al. 1998).  The antibody response to TI antigens can be stimulated without help from
antigen-specific T-cells, by cross-linking the surface immunoglobulins on the B-cell
surface. Although the TI-2 response can be evoked without T-cell help, the regulatory
T-cells have an influence on the magnitude of the response (Rijkers and Moshier 1985).
Both lymphokines and T-B cell interactions are shown to be required for an optimal
antibody response to pneumococcal PS (Griffioen et al. 1992a). The TI-2 response is
evoked later in life than is the TD response and shows no memory, affinity maturation,
or isotype switch (Mosier et al. 1977, Baker et al. 1981). The immune responsiveness to
TI-2 antigens begins during the first months of life and reaches adult levels by the age
of 5 years (Pabst and Kreth 1980).
One explanation for the poor responsiveness to PS antigens in early life is suggested to
be the late maturation of the B-cell subset responding to TI antigens. The cells activated
by PS antigens have been shown to be the CD5- subset of the B-cell population; the
appearance of these cells in ontogeny correlates with a child’s responsiveness to PS
antigens, both occurring at around two years of age (Barrett et al.1992).  Secondly,
pneumococcal PS is able to activate the alternative complement pathway and to bind the
split product, C3d, of complement factor C3 in the absence of antibodies. The
complement receptor 2 (CR2) is a receptor on the B-cells that binds to the PS
complexed to C3d. This interaction of the CR2 to the PS-C3d complex plays a key role
in B-lymphocyte activation, proliferation, and antibody production (Griffioen 1991).
Neonatal B-cells in the marginal zone of the spleen (that is supposed to be the site of
the initiation of the immune response to PS antigens) express significantly decreased
levels of CR2 as compared to such cells in adults (Timens et al. 1989). Thus another
explanation for the neonatal unresponsiveness to PS antigens may be the lower
expression of this CR2 in infants than in adults (Griffioen et al.1992, Griffioen et al.
1993). Furthermore, the capacity of capsular polysaccharides to activate complement
varies (Hostetter 1986), which might explain the variation in immunogenicity between
different serotypes.
Another typical characteristic of PSs as antigens is that these antigens are distributed
through body fluids (Spinola et al.1986, Darville et al. 1992), which may allow them to
reach lymphatic tissues at distant sites. Asymptomatic carriage of encapsulated bacteria
is reported to be associated with antigenuria (Murphy et al. 1989, Manary et al. 1993),
and children immunised with PRP- or Hib-conjugate vaccines have been shown to
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excrete PRP antigen in their urine (Spinola et al. 1985, Miller et al. 1995). This suggests
that PS antigens are released into the circulation, both after mucosal invasion and after
parenteral administration of the antigen.
B lymphocyte
antibodies
B. Response to conjugate vaccine
A. Response to polysaccharide vaccine
B
B lymphocyte
T lymphocyte
protein molecule
        polysaccharide
cytokines
MHC II
TCR
plasma
cell
B memory
cell
Figure 3.
T-cell independent and T-cell dependent antibody responses to PS or PS-protein
conjugate antigens. (Modified from Åhman 1999, Dissertation, University of Helsinki).
The immunogenicity of PS antigens can be enhanced by coupling them to a protein
carrier (Avery and Goebel 1929, Goebel 1939), which converts them into TD antigens
(Schneerson et al. 1980, Schneerson et al. 1983). A hypothesis as to how conjugation of
a PS to a protein carrier enhances the response is presented in Fig 3. The PS-protein
complex is internalized in a B-cell via its PS-specific surface-Ig receptor. This leads to
processing of the protein in the B-cell and presentation of the peptides to the Th cells in
MHC complexes on the surface of the (PS-specific) B-cell (Lanzavecchia 1985,
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Lanzavecchia 1986). Repeated immunisations increase the number of carrier protein-
specific Th-cells that provide help to PS-specific B-cells, resulting in differentiation of
the B-cells into memory or plasma cells.
4. 2. Systemic antibodies to polysaccharide antigens
In adults, parenterally administered  PS antigens are able to induce systemic antibodies.
The majority of the PS-specific antibodies detected in serum consist of IgG, but the fold
increases of the specific IgG remain lower than the fold increase of  PS-specific IgA
(Heilmann et al. 1987,  Lue et al. 1988, Tarkowski et al. 1989, Tarkowski et al. 1990).
This is in contrast to protein antigens, which mostly enhance IgG responses.
Furthermore, a marked proportion of the pneumococcal PS-specific IgG is shown to be
of the IgG2 subtype (Siber et al. 1980,  Barret et al. 1986, Soininen et al. 1999)
differing  from the IgG1 response seen to protein antigens (Seppälä et al.1984, Sarnesto
et al.1985). The IgG1/IgG2 ratio of the pneumococcal PS-specific response is also
altered when the PS is conjugated to a protein carrier; a higher proportion of IgG1 is
seen after PS-conjugate than after pure PS (Soininen et al. 1999). A similar difference
is shown to appear in IgA antibodies; the PS-specific antibodies mostly consist of the
IgA2 subtype, whereas the protein-specific IgA is of the IgA1 isotype (Heilmann et al.
1988, Lue et al. 1988, Tarkowski et al.1990).
In children, the response to PS antigens is age-dependent, and maturation of the
response differs with the type of PS antigen. The pneumococcal serotypes 3, 4, 8, 9N,
and 18C  induce good antibody responses in pre-school-age children and even in
infants, whereas the responses to other Pnc serotypes tested remain poor (Koskela et al.
1982). It has also been suggested that children with recurrent AOM may have a reduced
ability to respond with the IgG class antibody to the Pnc PS types most frequently
causing AOM (Prellner et al. 1984). However, children with pneumococcal AOM have
been shown to elicit serum antibodies to the infecting capsular serotype. Antibodies of
the IgG and IgM isotypes  have been detected in 25% of the children infected (Sloyer
et al. 1974). Recent Finnish studies have shown serotype-specific IgG and IgM in serum
even at the onset of the disease, and 36% of the children showed a twofold or greater
increase in antibody concentration in the convalescent sera (Koskela et al. 1982); such
responses were seen more frequently in older children. In a study by Virolainen et al.
(1996) 29% of children with pneumococcal AOM showed a serum response to
pneumococcal PS. In addition to AOM, pneumococcal PS-specific antibodies have been
reported to be present in half the children with pneumonia five days after onset of the
disease (Nohynek et al.1995). Furthermore, asymptomatic carriage of encapsulated
bacteria has been shown to induce systemic PS-specific responses (Greenfield et al.
1972, Granoff et al. 1980, Gray et al. 1981). Because carriers are asymptomatic, the
serum antibody response can be presumed to be a result of local antigenic stimulation
of lymphocytes in the nasopharynx, i.e., mucosal immunisation, followed by clonal
expansion and trafficking of antigen-secreting cells throughout the body.
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The first experience with PS-protein conjugates was gained with Hib conjugate
vaccines, which have proven both immunogenic and efficacious in preventing invasive
Hib infections in small children and infants (Käyhty et al.1987, Lepow et al. 1987,
Eskola et al.1985 and 1990, Ward et al.1990, Santosham et al.1991, Black et al. 1992,
Booy et al.1994,  Mäkelä et al. 1990 and 1995). Interestingly, vaccination with Hib has
also been shown to reduce the nasopharyngeal carriage of Hib bacteria (Mohle-Boetani
1993, Murphy et al. 1993, Takala et al.1993), suggesting a protective activity for
conjugate vaccines at mucosal surfaces.
 
4. 3. Mucosal antibodies to polysaccharide antigens
Parenteral administration of PS antigens also induces mucosal antibody responses (Lue
et al. 1988, Kauppi et al. 1995). Mestecky has suggested that systemic administration of
antigens boosts an effective S-IgA response only in situations where an immunised
individual has previously encountered the same antigen, or cross-reacting antigens, via
the mucosal route (Mestecky 1987). This hypothesis is supported by the studies of
Svennerholm et al. (1980),  who demonstrated that the S-IgA response in saliva and
milk to a parenteral cholera vaccine was significantly higher in lactating Pakistani
women, who were expected to be naturally exposed to cholera antigens, than in
lactating Swedish women, not exposed to cholera. Enteric bacteria colonising the
intestinal mucosa also have cross-reacting antigens with encapsulated respiratory
pathogens and can thus give rise to antibodies cross reacting with capsular PS of Pnc
and Hib (Robbins et al. 1972 and 1975). On the other hand, the PS antigens are shown
to be widely dispersed in body fluids (Spinola et al. 1986, Darville et al. 1992), which
would allow parenterally administered PS to reach the lymphatic inductive tissues at
mucosal sites and induce local S-IgA production, even without previous exposure to the
antigen at mucosal sites.
Although PS antigens are unable to induce serum antibodies in infants and small
children, mucosal antibodies can be elicited even at an early age. Mucosal antibodies
have been detected in children less than one year of age after systemic Hib infection
(Pichichero et al.1981). Detection of the mucosal immune response, which is
independent of the systemic response, suggests that functional maturation of the
mucosal immune system takes place earlier in ontogeny than that of the systemic
immune system, at least in respect to PS antigens (Pichichero et al.1981). Immunisation
with PRP vaccine  also  induces greater serum antibody responses in adults than in
children (>18 months of age), but induces comparable S-IgA responses in saliva and
nasal washes, further suggesting earlier maturation of the mucosal immune system
(Pichichero et al.1983).
PS-specific antibodies induced in secretions after immunisation are mostly IgA
(Pichichero et al.1983, Lue et al.1988, Kauppi et al. 1995). In contrast to protein
antigens that induce IgA1-dominant S-IgA responses, the IgA response to
polysaccharide antigens is dominated by IgA2 in adults (Mestecky and Russel 1986). In
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children, however, the S-IgA response to conjugated PS is mainly IgA1 (Kauppi-
Korkeila et al. 1998, Korkeila et al. 1999).
It is generally believed that administration of antigens via the mucosal route results in
better mucosal antibody responses than does systemic administration. Polysaccharides
cannot, however, be administered mucosally as such for antibody induction. Therefore
mucosal adjuvants are needed, in order to allow the PS antigen through the mucosal
barrier to reach the lymphatic tissues and to enhance the release of immune mediators
needed for antibody production (Mestecky et al. 1997). Very little is yet known about
the immunogenicity of PS-antigen or PS-protein conjugates in humans when
administered via the mucosal route. Several experimental studies, however, have
demonstrated induction of both mucosal and systemic antibody responses after mucosal
immunisation with these antigens. Intranasal or oral administration of bacterial PS-
containing liposomes in mice has been shown to induce PS-specific S-IgA in the lung
(Abraham 1992) and in the faeces when cholera toxin (CT) has been co-administered
orally with PncPS (Van Cott et al.1996). Furthermore, the S-IgA response in the lung
has been shown in the mouse when PncPS is conjugated to cholera toxin subunit B
(CTB) and administered orally or intranasally, and the response has been enhanced by
entrapping the conjugate in alginate microspheres (Seong et al. 1999).  Intranasal
administration of PncT in mice, together with a glyceride-polysorbate adjuvant, has also
been shown to elicit S-IgA in saliva (Jakobsen et al. 1999). 
Moreover, pneumococcal AOM in children has been shown to elicit a PS-specific IgA
response both in MEF (Sloyer et al. 1974, Karjalainen et al. 1990) and in
nasopharyngeal aspirates (NPA) (Virolainen et al. 1995). In the early phase of AOM,
IgG and IgM antibodies that seem to be derived from serum appear in the middle ear,
and a local S-IgA response to pneumococcal PS has been shown to develop slowly
during the course of AOM (Karjalainen et al.1990). However, even more efficient
induction of mucosal antibodies may be induced in children after symptomless Pnc
carriage than after AOM. In a recent study, salivary antibodies were detected in 65% of
the children carrying Pnc and in 53% of the children with pneumococcal AOM (Kauppi
et al.1998). 
4. 4. Antibody-secreting cells
The induction of antibody responses can also be studied by measuring the number of
antibody-secreting cells (ASC) in various lymphatic tissues or in the peripheral blood.
As the B cells are constantly circulating through the lymphatics and blood back to the
peripheral tissues (Gowans et al. 1964), cells committed to mucosal sites are also
present in the peripheral blood for a limited period of time, before homing to different
exocrine tissues. The appearance of these antigen-specific ASC can thus be measured
in peripheral blood after an antigen challenge. It is generally beliewed that antigens
introduced to the host via mucosal sites may induce IgA-dominant ASC responses and
S-IgA responses, whereas parenterally administered antigens may typically induce IgG-
dominant ASC responses and systemic IgG in serum. However, this is not the case in
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respect to PS antigens that tend to induce IgA-dominant responses even when
administered parenterally. In adults, an ASC response to PS antigens has been shown to
consist mostly of IgA-secreting cells (Kerl and Fauci 1983, Heilman and Pedersen
1986, Munoz and Insel 1987, Lue et al. 1988, Tarkowski et al. 1989), whereas the
response detected to protein antigens is clearly dominated by IgG ASC (Lue et al.
1994).
As mentioned above, Mestecky and Russel (1986) have suggested that the IgA-
dominant response seen after systemic administration of the PS antigens is due to earlier
contact with the same, (or cross-reacting) antigen at a mucosal site. Thus, B-cells would
be stimulated in lymph nodes near the injection site, and cells already committed to IgA
production would then migrate via the circulation to mucosal sites to secrete IgA.
Another explanation is that PS antigens may reach mucosal sites and lymphatic tissues
in which the micro-environment favours IgA commitment of B cells (Strober et al.
1991,Weinstein and Cebra 1991).
PS conjugated to a protein carrier is shown to induce higher numbers of anti-PS ASCs
in the peripheral blood than does pure PS. Furthermore, the IgG /IgA ratio of the ASC
response is increased as compared to the response to PS (Lue et al. 1990). The  IgA-
ASC response detected in adults is mostly of the IgA2 isotype after administration of
PS antigens, in contrast to the IgA1 isotype seen in response to protein antigen. Studies
with pneumococcal serotype 12F showed higher IgA1 ASC responses when the PS was
conjugated to a carrier protein than with PS alone (Lue et al. 1990), but the IgA-ASC
response after a PS conjugated to a protein carrier is still dominated by the IgA2 isotype
(Lue et a.l 1990, Tarkowski et al. 1990). In infants, the IgA response is shown to consist
mostly of IgA1-secreting cells after immunisation with a PS conjugate vaccine
(Barington et al. 1994). 
5. Pneumococcal vaccines
5. 1. Systemic vaccines
The first immunisation studies with purified pneumococcal PS were carried out in the
1930's, after the central role of capsular PS as a pneumococcal virulence factor (Dubos
and Avery 1931) and the immunogenicity of PS (Francis and Tillet 1930) were
discovered (reviewed by Fedson et al.1999). The first pneumococcal vaccine was
generated by MacLeod and his co-workers in 1945 (MacLeod et al.1945). Today, the
only pneumococcal vaccines that are registered and in use are the 23-valent PS
vaccines: PneumovaxR (MSD), Pnu-immuneR (Wyeth Lederle vaccines), and Pneumo
23R (Pasteur-Mérieux-Connaught). The types included in these comprise 90% of the
serotypes causing invasive disease in developed countries. These vaccines are
immunogenic and protective against invasive pneumococcal infections in adults and in
older children  (Austrian et al. 1976, Leinonen et al. 1982, Leinonen et al. 1986, Riley
et al. 1986, Sims et al.1988, Shapiro et al. 1991). In children less than two years of age,
however, they are not immunogenic (Mäkelä et al. 1983, Leinonen et al. 1986).
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The first experimental studies with PS-protein conjugates were already being carried
out in the late 1920's and 1930's (Avery and Goebel 1929, Goebel 1939). The present
pneumococcal PS conjugate vaccines (Table 2), however, have been developed and
designed during the last few decades, based on the experience acquired from conjugate
technology gained with the Hib conjugate vaccines (Schneerson et al.1980).
Pneumococcal conjugates have proven immunogenic in small children and infants
(Käyhty et al. 1995, Åhman et al. 1996, Anderson et al.1996, Dagan et al.1997, Åhman
et al.1998, Rennels et al.1998).These vaccines have also been shown to be
immunogenic in high-risk children, e.g., in children with recurrent respiratory infections
(Sorensen et al. 1998) and in children with recurrent AOM (Breukels et al. 1999).
Recently, pneumococcal PS conjugate has been shown to be efficacious in preventing
invasive infections in children and infants (Black et al.1998) and in reducing the
nasopharyngeal carriage rates of pneumococci (Dagan et al.1996). In addition, some
preliminary data suggest a 7% reduction in all AOM visits, irrespective of etiology
(Black et al.1999). The specific data on pneumococcal AOM still remains to be studied.
Finally, whether the reduced mucosal carriage is due to serum antibodies or induction
of mucosal response needs elucidation.  
5. 2. Mucosal vaccines
As mucosal administration of antigens is expected to be more effective in inducing
protection at mucosal sites than the systemic administration, intensive studies are aimed
at the development and testing of mucosal vaccines. Adjuvants that augment
penetration of antigens through the mucosal layers to reach lymphatic tissues and
enhance the immunological responses to vaccines administered via mucosal routes play
a key role in this process.  Another important advantage of mucosal vaccination would
be its convenience for those immunised, not to mention the easier performance of the
vaccination programs. The most practical routes of mucosal vaccination in humans
would be oral and nasal administration of antigens. For prevention of respiratory
infections, the most logical administration would be the intranasal route. Several
experimental studies with pneumococcal PS or PS-conjugates administered intranasally
or orally have been carried out, and mucosal S-IgA and systemic antibody responses
demonstrated in the mouse and rat (Abraham 1992, van den Dobbelsteen et al. 1992 and
1995, Van Cott et al.1996,  Flanagan et al. 1999, Seong et al. 1999, Jakobsen et al.
1999). Human studies are, however, still scarce, partly because of the lack of mucosal
adjuvants acceptable for human use. 
Two potent enterotoxins, cholera toxin and Escherichia coli heat-labile enterotoxin, are
powerful mucosal adjuvants that augment S-IgA and systemic IgG responses to co-
administered antigens (Holmgren et al.1993, Levine and Dougan 1998). Mutants  that
show reduced toxicity, but still sustain sufficient adjuvant activity, have been
engineered from the wild-type forms (Douce et al.1995, Douce et al.1997, Fontana et al.
1995). Another kind of nasal adjuvant based on caprylic-capric glycerides dissolved in
polysorbate 20 and water, Rhino Vax, is a non-toxic adjuvant and thus acceptable for
human use (Gizurarson et al. 1996). It enhances transepithelial flux and has been
22
proven to induce immunogenicity to protein antigens: diphtheria and tetanus toxoids,
after intranasal administration in humans (Aggerbeck et al. 1997).  Recently, this
adjuvant was also shown to enhance the systemic and mucosal responses after
intranasal administration of pneumococcal conjugate vaccine, PncT, in mice and to
protect mice against invasive pneumococcal infections (Jakobsen et al. 1999).
Protection against colonisation and invasive disease has also been shown in mice after
intranasal immunisation with pneumococcal PS conjugated to the cholera toxin B
subunit (Seong et al. 1999). In addition to adjuvants mentioned above, novel strategies,
including enclosure of antigens in biodegradable microspheres, proteosomes,  or
liposomes, or their expression in viral and bacterial vectors, and even in plants, are
currently under research in modern vaccinology (reviewed by Mestecky et al. 1997 and
Levine and Dougan 1998).
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AIMS OF THE STUDY
The aim of the thesis was to characterise the circulating antibody-secreting cell (ASC)
response and the mucosal antibody response induced by pneumococcal polysaccharide
(PncPS) antigens
  ]  in adults and toddlers immunised parenterally with pneumococcal vaccines
  ]  in children with pneumococcal acute otitis media (AOM)
and to evaluate the relevance of the ASC response as a marker of the local IgA
response.
To this end we measured
  ]  the number of PncPS specific ASCs in the peripheral blood
  ]  the PncPS specific antibodies in saliva and nasopharyngeal aspirates (NPA)
and compared the results of the two measurements. The overall immunogenicity of the
vaccines was evaluated by measuring the serum antibody response to PncPS.
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MATERIAL AND METHODS
This thesis consists of  four separate studies: three vaccine studies (I-III) and one study
on acute otitis media (IV). Each vaccine study was carried out with healthy volunteers,
each of them participating in only one of the studies. The vaccines and the subjects for
each of the vaccine studies are shown in Table 2. In two of them the study subjects were
adult volunteers (I-II,) and in one the subjects were toddlers (III). The otitis media
patients were children aged 9 to71 months. 
1. Study subjects
1. 1. Vaccinees
The adult volunteers (n=40) participating in the studies were healthy students or
laboratory personnel (aged from 18 to 56 years). None of them had received a
pneumococcal vaccine earlier. During the study they were vaccinated  intramuscularly
in the deltoid muscle (dose 0.5 ml). In the first study, eight volunteers were vaccinated
with the PncPS vaccine, and ten volunteers with the PncOMPC vaccine (I).  In the
second study, 22 volunteers were vaccinated with PncD or PncT vaccine  in a
randomised, double-blind trial (II) (Table 2). 
A group of 40 healthy children, mean age 24 months (range 23 to 25 months), were
enrolled in the third study and vaccinated intramuscularly in the deltoid muscle, each
receiving one of the four vaccine formulas in a randomised, double-blind trial (Table 2).
No other vaccines were given at the same time. All the children had previously received
the immunisations recommended by the Finnish national immunisation programme, i.e.,
DTP (diphtheria-tetanus-pertussis vaccine) at the ages of 3, 4, and 5 months, Hib
conjugate vaccine at the age of 4, 6, and 14 to18 months, and the inactivated polio
vaccine at the age of 6 and 12 months.
1. 2. Patients with acute otitis media
Streptococcus pneumoniae was cultured in the MEF of 30 children with AOM enrolled
in a study on pathogenesis of AOM at the Department of Otolaryngology at the Helsinki
University Hospital during the winter of 1991-1992 (Virolainen et al. 1994). Samples
for this analysis were available from 17 of them. Children, aged 9 months to 5 years
(median 4 years), were defined as having AOM on the basis of pneumatic otoscopic
findings suggesting middle ear fluid (MEF) behind an inflamed tympanic membrane,
and at least one of the following symptoms of acute infection: otalgia, tugging at or
rubbing of the ear, rectal/axillary temperature at least  38.0bC, irritability, restless sleep,
acute gastrointestinal symptoms (vomiting or diarrhoea), or other simultaneous
respiratory infection. Patients with secretory otitis media, tympanostomy tubes,
spontaneous perforation of the tympanic membrane, or antibiotic treatment within one
week before enrolment were excluded.
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2. Vaccines
The pneumococcal polysaccharide vaccine PncPS (PneumovaxR, Merck Sharp &
Dohme, West Point, PA), is a mixture of  capsular polysaccharides of 23 different types
(25 µg/dose of each). The pneumococcal conjugate vaccine PncOMPC (Merck
Research Laboratories) is a mixture of  four pneumococcal capsular polysaccharides,
each separately conjugated to the meningococcal outer membrane protein complex of
group B N. meningitidis. The polysaccharide/protein ratio in the vaccine varies from
0.11 to 0.17 depending on the serotype. The pneumococcal conjugate vaccine, PncD,
(Pasteur-Mérieux-Connaught, USA) is a mixture of four pneumococcal polysaccharides
conjugated to diphtheria toxoid. The PncT vaccine (Pasteur-Mérieux-Connaught,
France) is a mixture of four conjugates consisting of the pneumococcal polysaccharides,
each separately conjugated to tetanus protein. Two different dosages of the PncD and
PncT conjugates were used: each dose of the vaccines contained either 3µg (PncD03
and PncT03) or 10µg (PncD10 and PncT10) of each polysaccharide. The PS/protein
ratios for each of the PS varied from 2.0 to 3.1  in PncD and from 1.4 to 2.2 in PncT,
respectively. No adjuvants were used in any of the vaccines.
Table 2. Vaccines used in the studies
Study
vaccines 
Study PS/dose serotypes carrier protein The number of
vaccinees
PncPS1) I 25µg 23 serotypes2) none 8 adults
PncOMPC I 1µg 6B, 14, 19F, 23F the meningococcal
outer membrane
protein complex of
N. meningitidis
10 adults
PncD II 10µg 6B, 14, 19F, 23F diphtheria toxoid 12 adults
PncT II 10µg 6B, 14, 19F, 23F tetanus protein 10 adults
PncD III 3µg 6B, 14, 19F, 23F diphtheria toxoid 10 toddlers
PncT III 3µg 6B, 14, 19F, 23F tetanus protein 10 toddlers
PncD III 10µg 6B, 14, 19F, 23F diphtheria toxoid 10 toddlers
PncT III 10µg 6B, 14, 19F, 23F tetanus protein 10 toddlers
1)  PneumovaxR
2)   1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F
3. Specimen collection
3. 1. Vaccine studies
Blood samples from the vaccinees were collected for enumeration of antibody- and
immunoglobulin-secreting cells (ASC and ISC) and for antibody measurement before
and after immunisation (Table 3). ASC/ISC analysis was performed on 10 to 20 ml of
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heparinized blood within an hour from sampling. Serum samples (5 ml of serum) were
stored at -20o C until analyzed. Unstimulated saliva samples (1 ml) were collected from
the vaccinees with a plastic pipette and stored at -70oC until analyzed. Frozen samples
were thawed only once, when analyzed. Nasopharyngeal samples were collected by
swabbing (Transpocult, Orion Diagnostica, Espoo, Finland) on days 0 and 28 and
transported to the bacteriological laboratory to test for carriage of Streptococcus
pneumoniae.
Table 3.          Schedule for sampling
days after immunisation                        
blood for      serum for saliva for
Vaccine Study Elispot EIA EIA
PncPS/PncOMPC I 0, 5, 7, 9, 14, 28 0,  28 0, 5, 7, 9, 14, 28
PncD/PncT; adults II 0, 7, 28 0,  28 0, 7, 28
PncD/PncT; toddlers III 7 0, 7, 28 0, 28
3. 2. Acute otitis media study
Serum and nasopharyngeal aspirate (NPA) samples from the AOM patients were
obtained at the initial visit in the acute phase, and at the control visit 2 weeks later. The
NPA sample was collected by insertion of a suction catheter through a nostril as
described by Virolainen et al. (1995a).  MEF samples were obtained at the initial visit
only.  A whole-blood sample for ASC analysis was taken on day 7 after the initial visit
in order to asses the peak number of ASC.  
The nasopharyngeal swabs and MEF and NPA samples were cultured and the isolated
bacteria identified by standard methods (Balows et al. 1991). Pneumococcal strains
were serotyped/grouped by counterimmunoelectrophoresis (CIE) or latex agglutination
(groups 7 and 14) (Leinonen et al. 1980) with type-specific antisera from Statens
Seruminstitut, Copenhagen, Denmark.
4. Serological assays
4. 1. Antigens for the assays 
Pneumococcal capsular polysaccharide antigens (serotypes 6B, 9, 14, 19F, 23F) were
from the American Type Culture Collection, Rockville, MD, USA. Pneumococcal C-
polysaccharide (CPS) was obtained from Lederle-Praxis, West Henrietta, NY, USA.
Diphtheria toxoid and tetanus toxoid were produced by the Vaccine Laboratory at the
National Public Health Institute, Helsinki, Finland. In the AOM study (IV), ASCs and
antibody concentrations were measured against the same type/group as cultured in the
MEF and against one heterologous control serotype (either 6B, 14, 19F or 23F).
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4. 2. Antibody-/Immunoglobulin-secreting cells
Specific antibody-secreting cells (ASCs) to pneumococcal polysaccharide and to both
diphtheria and tetanus toxoids, as well as the number of total immunoglobulin-secreting
cells (ISCs), were measured with an enzyme-linked immunospot assay  (ELISPOT )
(Czerkinsky et al. 1983, Sedgwick and Holt 1983). The mononuclear cells were
separated from heparinised blood with Ficoll-Paque density gradient centrifugation
(Pharmacia, Uppsala, Sweden) and adjusted to a concentration of 2 x 106 cells/ml in
RPMI culture medium supplemented with 10% heat-inactivated fetal calf serum,
gentamicin (15 µg/mL), and L-glutamine (3 mg/ml). Microtiter plates were coated with
pneumococcal polysaccharides as for EIA (Käyhty et al. 1995) and blocked with 1%
bovine serum albumin (BSA) in PBS for 30 min at 37oC. For enumeration of diphtheria-
and tetanus-toxoid-specific cells, the plates were coated with diphtheria toxoid: 2.5
Lf/ml and  tetanus toxoid: 0.5 Lf/ml.
Lymphocytes were allowed to secrete antibodies in the wells. Cells secreting IgA, IgG,
and IgM were measured from the vaccinees (I-III) and cells secreting IgA, IgA1, IgA2,
IgG, and IgM were measured from the AOM patients (IV). Monoclonal antibodies to
human IgA (Oxoid M26012, Unipath Ltd, Hampshire, England), IgA1 or IgA2 (Nordic,
MaHu/Iga1/asc NI69-11 or MaHu/IgA2/asc NI 512, Tilburg, the Netherlands), were
added to the wells, and the plates were incubated overnight at room temperature before
alkaline phosphatase-conjugated antisera to mouse IgG (Jackson H&L 315-055-045,
West Grove, PA) was added. Alkaline phosphatase-conjugated porcine  anti-IgG and
anti-IgM antibodies (Orion) (I, IV) or goat anti-IgG and anti-IgM antibodies (Sigma;
A3188, A3437) (II, III) were used. The substrate (5-bromo-4-chloro-3-indolyl-
phosphate, Sigma) was applied in agarose. Spots were counted under low
magnification. 
Results were expressed as the number of IgA, IgA1, IgA2, IgG, and IgM ASC/106 cells.
The peak number of ASCs, detected on day 7 or 9, was the chosen value for the ASC
response. Five or more ASCs/106 cells on day 7 after immunisation was considered  a
response.
4.3. Measurement of antibodies
Type-specific pneumococcal capsular polysaccharide antibodies were measured by EIA
in paired saliva (I-III), NPA (IV) and serum samples (I-IV) after neutralisation of CPS
antibodies (Käyhty et al. 1995, Virolainen et al. 1995b, Virolainen et al. 1996,  Åhman
et al. 1996), which can be induced by the pneumococcal vaccines (Skov Sorensen and
Henrichsen 1984). For the vaccine studies, the reference serum pool,  89-SF, (Quataert
et al. 1995) was used, and the serum antibody concentrations  were expressed as ug/ml.
The saliva results in Study I and the NPA results in the AOM study (IV) were expressed
as end-point titers read at an optical density (OD) of  0.3. Saliva and NPA samples were
centrifuged at 15 000 rpm for 10 min at room temperature before analysis. The
supernatant was used for pneumococcal enzyme immunoassays (I-IV) and measurement
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of total IgA by a radial immunodiffusion technique (Mancini) (LC-Partigen IgA,
Behringwerke, Marburg, Germany) (II-IV). For measuring IgA and secretory
component (SC), monoclonal antibodies to human IgA (Oxoid M26012) and to human
SC (Sigma 1-6635) were used, followed by alkaline phosphatase-conjugated antiserum
to mouse IgG (Jackson H&L 315-055-045). Saliva and NPA samples were analyzed in
triplicates with plates coated with PBS used as blank plates for each assay (Kauppi et al.
1995, Virolainen et al. 1995). 
The specific IgA concentrations in saliva were divided by the concentration of total IgA
in each sample and expressed as ng of specific IgA /ug of total IgA to standardise the
degree of dilution in each sample (II-III). Samples with undetectable anti-Pnc
polysaccharide IgA were assigned values that were one half log less than the detection
limit for each pneumococcal serotype: 1 ng/ml for serotypes 6B, 14, 23F, and 2.5 ng/ml
for serotype 19F. In Study I, the saliva results are given as EIA-units (OD-readings). A
twofold rise (specific/total IgA) between day 0 and 28 was regarded as a response (I-
III). The saliva results for specific IgG were given as ng/ml (II-III). Samples with
undetectable anti-Pnc polysaccharide IgG were assigned the values (half log less than
the detection limit) 2 ng/ml for serotype 6B and 3 ng/ml for serotypes 14, 19F, and 23F.
The NPA results for specific IgA in the AOM patients were calculated by subtracting
the background OD from the specific OD, and dividing by concentration of total IgA in
the sample (IV). If the total IgA was below the detection limit (4.5 IU/ml), the value
2.25 IU/ml was used. A threefold rise between the acute and convalescent phase results
(specific/total IgA) was regarded as a response. The NPA results for specific IgG and
IgM were calculated as above but not compared to total IgA.
5. Statistical analyses
The results are given as geometric mean (GM) of ASCs or antibody concentrations
(GMC).The comparison of the mean in the different vaccine groups (for each serotype)
was done with ANOVA, by use of log-transformed data. If significant differences were
found, pairwise comparisons between vaccine groups were performed by the Bonferoni
test (adults), LSD-test (least significant difference; assuming equal variances) (III), or
Tammhane's T2-test (assuming unequal variances) (III). The T-test was used when
toddlers were compared to adults. The significance of the correlation between the
number of ASCs and the antibody concentrations was estimated by Pearson's or
Spearman's correlation (I-III). Proportions of children with  antibodies or antibody
responses to each of the serotypes were compared with McNemar’s test (III). The paired
t-test with log transformed data was used when the ASC responses of the AOM patients
were compared in the two age-groups (IV). 
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RESULTS
1. Antibody-secreting cell response
1.1. ASC response in the vaccinees
Altogether 40 adult volunteers and 40 toddlers were vaccinated with one of the study
vaccines (Table 2). Few pneumococcal polysaccharide-specific ASCs could be detected
in the peripheral blood on day 0 in adults (I, II). After immunisation, their number
increased rapidly, so that the peak number of ASCs was seen on day 7 or 9 after
immunisation (I). On day 7 after immunisation ASCs were seen in all vaccinees to each
of the serotypes (I, II). Thereafter, the number of ASCs decreased, and on day 28 no
ASCs could be detected (I). The peak number of ASCs varied by vaccine used. As a
whole, the responses in adults were higher after PncT and PncD conjugates than after
PncPS and PncOMPC conjugate (p<0.001, except:  p=0.034 for serotype 14 and
p=0.004 for serotype 19F in the comparison of PncPS with PncD, and p=0.004 for
serotype 14 in the comparison of PncPS with PncT) (Fig 4).
In toddlers, the ASC response was studied only on day 7 after immunisation.
Pneumococcal polysaccharide-specific IgA, IgG, and IgM ASCs could be detected in
all the 40 vaccinees (III). This was true for all the serotypes (for serotype 23F only 29
samples were analyzed),  with one exception (one child did not respond to serotype
19F). In toddlers the responses were lower than in adults after PncD and PncT
(p<0.001, except for p=0.015 for serotype 14 in comparison with PncT responses), but
comparable to those seen in adults after PncPS  (Fig 4). 
The ASC response consisted mostly of IgA- and IgG-secreting cells, whereas the
number of IgM ASCs remained low (2-28 ASC/106 cells) (I-III). The dominant antibody
class in the ASC response in most of the cases was IgA  (Fig 4). In adults, this was true
for all four serotypes after immunisation with PncPS and PncD and for two serotypes
after PncOMPC (I, II). In response to PncT, however, the number of IgG ASCs
exceeded the number of IgA ASCs (II). The peak number of IgA-ASCs (GM) was
higher after vaccination with PncPS than after PncOMPC, but the number of IgG ASCs
did not differ between PncPS and PncOMPC (I) (Fig 4). On the other hand, the number
of IgA ASCs did not differ between PncD and PncT, but the number of IgG ASCs was
3.0 to 4.4-fold higher after immunisation with PncT than after PncD; the difference was
statistically significant for serotypes 6B, 19F, and 23F  (p=0.02). In toddlers, the ASC
responses to all the serotypes were dominated by IgA (III) (Fig 4).
In the PncD and PncT vaccine groups we also measured ASC response to the carrier
proteins, diphtheria toxoid or tetanus protein (II, III). The ASC responses were
completely specific: no ASCs to diphtheria toxoid were detected in vaccinees
immunised with PncT nor were any ASCs to tetanus protein found in vaccinees
immunised with PncD. The ASC responses to the carrier proteins were clearly
dominated by IgG in all the vaccinees (Fig 5).
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Figure 4.
The geometric mean number of IgA- and IgG-ASCs to pneumococcal serotypes 6B, 14,
19F, and 23F on day 7 after parenteral immunisation with the pneumococcal vaccines
(with 95% confidence intervals shown). 
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Figure 5.
The geometric mean number of ASCs to the carrier proteins (diphtheria or tetanus
toxoid) on day 7 after immunization with the pneumococcal conjugate vaccines PncD
and PncT in adults and toddlers (with 95% confidence intervals shown).
1. 2. ASC response in children with pneumococcal acute otitis media
ASCs to the capsular PS of the pneumococcal type isolated from the MEF could be
detected in all of the 17 patients studied, varying from 7 cells to 1100 ASC/106 cells (all
immunoglobulin classes combined). The geometric mean of the ASC response was
clearly age-dependent; whereas the overall geometric mean (GM) was 32 ASC/106
cells, it was 63 ASC/106 cells in children older than 24 months and 18 ASC/106 cells in
these vaccinees (p = 0.03). Seven (78%) of the nine older children, and three (38%) of
the eight younger children had at least 15 ASC/106 cells. The ASC response was
independent of gender.
Three children, all younger than 24 months, had their first AOM episode during the
study (IV: Table). The causative agents were of serogroups 6 and 19 (two children).
These children had only a low or no ASC response, but did not differ significantly from
the other five children in this age-group (IV: Table). On the other hand, four older
children had had at least 10 previous AOM episodes. Their infection was caused by
group/type 9, 14 (two cases), or 19, and they all had an ASC response, although a
weaker one than that of each of the other five children in this age-group. 
In ten of the children in the study, the dominant antibody class was IgA. IgG-ASC were
dominant in one child and IgM-ASC in another; both of these children had had over 10
AOM episodes in their lifetimes.
In order to confirm the specificity of the ASC response in the AOM patients, we
enumerated the ASC response to a Pnc-type (6B, 14, 19F, or 23F) different from the
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type cultured in MEF. Most of the ASCs in the control assays were IgA-producing cells
(IV: Table), and IgG or IgM-ASC were detected in only few patients. The number of
IgA-ASCs thus detected was less than 10 ASC/106 cells in all the children, supporting
the specificity of the assay (Table in IV). 
Table 4. Number of vaccinees  with  IgA antibodies in saliva before (pre) and after (post)
vaccination and the number of those with a twofold or higher increase in salivary IgA
concentration.
number of positive 
 
     response         number of positive      response        
Pnc-type  
 
  pre post number % pre post number %
PncPS, n=8; adults                PncOMPC, n=10; adults
6B   3 4 2 25 3 3 - -
14   7 7 2 25 8 6 - -
19F   6 7 2 25 8 7 1 10
23F   2 2 2 25 5 3 - -
PncD, n=12; adults       PncT, n=10; adults        
6B   2 4 5 42 2 3 2 20
14   7 10 5 42 6 8 3 30
19F   7 9 5 42 5 6 3 30
23F   4 6 6 50 7 7 2 20
       PncD, n=20; toddlers  PncT, n=19; toddlers      
6B   0 4 2 11 2 9 8 50
14   2 2 1 6 - 11 10 67
19F  3 12 7 37 4 14 11 69
2. Antibodies to pneumococcal polysaccharide in saliva (Tables 4 and 5) 
Pneumococcal PS-specific IgA antibodies were already detected in the saliva of most of
the adult vaccinees before immunisation, most frequently to serotypes 14 and 19F (I,
II). In toddlers, PS-specific IgA antibodies were detected only occasionally before
immunisation (III). The increases in the IgA concentrations in adults were modest, but
could be seen on day 7 after immunisation (I, II). A total of eight IgA responses
(>twofold increase in salivary IgA concentration)  was seen in six of the eight vaccinees
(25% of the measurements showed a response) who had received PncPS, but only one
response was seen in the ten vaccinees who had received PncOMPC (I). The responses
were seen with equal distribution among the four serotypes (I). The 22 adults who had
received PncD or  PncT  showed a salivary response in 32% of the measurements (II).
The  specific IgA concentration on day 28 ranged from <3 ng/ml to 222 ng/ml. The
toddlers receiving PncD or PncT showed a more than twofold increase in 35% of the
measurements, most frequently to serotype 19F; the specific IgA concentrations in
saliva ranging from <3 ng/ml to 52 ng/ml on day 28.
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Salivary IgA antibody concentrations showed an excellent correlation with the secretory
component (SC) concentrations, indicating that the IgA measured was secretory in
nature. This was true both before and after (day 28) immunisation (r=0.93-0.97; I-III).
Table 5. Number of vaccinees  with  IgG antibodies in saliva before (pre) and
after (post) vaccination 
    number of positive           number of positive     
Pnc-type       pre post % post pre post % post
PncPS, n=8; adults PncOMPC, n=10; adults
6B - 1 13 1 2 20
14 - 1 13 2 4 40
19F - 2 25 3 4 40
23F - - - - - -
PncD, n=12; adults   PncT, n=10; adults
6B - 7 58 - 8 80
14 - 3 25 - 4 40
19F 2 7 58 - 2 20
23F - 7 58 - 6 60
PncD, n=20; toddlers   PncT, n=19; toddlers
6B - - - - 1 5
14 - - - - - -
19F - 1 5 - 1 5
IgG antibodies were rarely detected  in saliva before vaccination. In adults, IgG
antibodies could be detected on day 7, and more frequently on day 28. IgG responses
were seen in one of the eight volunteers who had received PncPS, in three of the ten
who had received PncOMPC, in seven of the twelve who received PncD and in eight of
the ten who received PncT. In toddlers, IgG antibodies were not detected in any of the
saliva samples before immunisation, and were found in only two samples even after
immunisation (day 28).
3. Antibodies to pneumococcal polysaccharide in serum  
Pneumococcal PS-specific IgG antibodies were  already present in the serum of all the
adult vaccinees before immunisation (I, II). The PncPS,  the PncD, and the PncT
vaccines  induced serum antibody responses to all the four PncPS studied. The GM fold
increase in IgG concentration varied from 3.5- to 6.0-fold after PncPS (I: Table 2) and
from 10- to 22-fold after PncD/PncT (II: Table 3), depending on the serotype.
Responses after PncOMPC were lower, less than 3-fold to each of the serotypes (I:
Table 2). The IgM responses remained lower in response to each of the vaccines. The
IgA concentrations were low before immunisation, below the detection limit in most of
the vaccinees. The GM increase in IgA concentration varied from 1.0- to 2.5-fold after
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PncOMPC (I: Table 2) and from 2.4- to 7.7-fold after the other vaccines (II: Table 3),
depending on the serotype.
In toddlers, IgG antibodies were detected in only 25 to 40% of the vaccinees before
immunisation, depending on the serotype.  IgM antibodies were present in 65 to 83% of
the 40 children. After immunisation, increased concentrations of IgM antibodies were
detected in virtually all vaccinees, and IgG antibodies were detected in 75 to 95%,
depending on serotype. Serotype-specific IgA antibodies were very rarely present in the
serum of the toddlers before immunisation (serotype 19F-specific antibodies detected
in three of the 40 vaccinees). After immunisation,  IgA antibodies were detected in 63
to 68% of the vaccinees on day 7 after immunisation and in 38 to 45% of the vaccinees
on day 28 (III: Table 1). Thus the GM IgA antibody concentration  was higher on day
7 than on day 28 (III: Fig 4). This was true for each of the vaccines (data not shown)
and for each pneumococcal serotype studied. The antibody concentrations in toddlers
on day 28 ranged from 0.9 µg/ml to 6.6 µg/ml for IgM and from 0.5 µg/ml to 6.4 µg/ml
for IgG (III: Fig 4).  On day 7, the GM  IgA concentration ranged from 0.2 µg/ml to 1.1
µg/ml, depending on vaccine and on the pneumococcal serotype measured.
4. Serotype-specific responses
Only a little variation in the ASC response was observed between the four serotypes  in
each of the vaccine groups (Fig 4), whereas serum antibody responses varied by
pneumococcal serotypes. Thus,  low serum antibody responses were often detected to
serotype 6B, (especially after PncPS and PncOMPC). The highest responses, in general,
were to serotypes 14 and 19F in adults and to serotype 19F in toddlers. In adults, the
secretory IgA antibodies in saliva were mostly to serotypes 14 and 19F before
immunisation, but the responses after vaccination occurred equally in all serotypes. In
toddlers, IgA antibodies were rarely detected before immunisation, but could be seen
most frequently to serotype 19F, although frequently also to other serotypes. Of the two
IgG-positive saliva samples detected in children, one was specific for serotype 6B, the
other for 19F. The latter was associated with an exceptionally high serum concentration
of serotype 19F-specific IgG (223 µg /ml). 
In children with AOM, the infection caused by serogroup 19 evoked the highest ASC
response, but group 23 was also associated with high ASC responses (Table in IV). The
ASC responses to other types were lower, but low responses were also detected in some
children to groups 19 and 23. Thus the magnitude of the response showed no clear-cut
correlation with the serotype causing the infection. 
5. Nasopharyngeal carriage of the pneumococci
S.  pneumoniae was identified by culture in the nasopharyngeal swabs from four adult
vaccinees before immunisation (I, II). One of them was colonised with the vaccine
serotype, 23F (I), and three with nonvaccine serogroups 3, 9, and 11 (II). None of the
vaccinees was colonised with  any pneumococcal serotype on day 28 after
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immunisation. S. pneumoniae was identified by culture in the nasopharyngeal swabs
from 8 children before immunisation (serogroups 6, 14, 15, 18, 19, and 23)  and in 11
children (7 new acquisitions) on day 28 after immunisation (serogroups 6, 18, 19, 23)
(III).  The ASC and antibody concentrations and responses of these culture-positive
vaccinees did not differ from those in the other vaccinees
The same serogroup as in MEF was cultured in the NPA sample of each of the 17
patients with pneumococcal AOM.  Pneumococcal group 19 was the most common
serogroup involved  (7 patients). Group 23 was cultured in 4 patients, group 6 in 3
patients, and type 14 in 2. One patient had an AOM caused by group 9.
6. Relation of salivary and serum antibodies to  number of antibody-secreting cells
In adults, the IgA response in saliva was associated with a high number of IgA-ASCs
(35/38 of the salivary responses were related to an IgA ASC response of >100 IgA
ASC/106 cells to the same serotype). On the other hand, a high ASC response was
detected only rarely when no salivary IgA response was seen. In Study I, more than 100
IgA ASC/106 cells were detected in 7 of the 62 cases that showed no salivary IgA
response to the same serotype. Furthermore, in most of these cases (5 of  7)  antibody
concentration was high before immunisation and a 1.2- to 1.9-fold increase in IgA
concentration was still seen. In Study II, more than 100 IgA ASC/106 cells were
frequently detected even when no salivary IgA response was demonstrated, but very
rarely (6 cases) when more than 1000 IgA ASC/106 cells were detected: also in Study II,
high salivary antibody concentrations were often already detected before immunisation,
but we did not attempt to correlate these cases with those with high ASC responses. In
toddlers (III),  IgA was rarely detected in saliva before immunisation. After
immunisation, a positive correlation was demonstrated between the salivary IgA
concentration (on day 28) and the number of IgA ASCs after PncD or PncT vaccination
in toddlers (r=0.57, p=0.01; IV: Fig 3).
The ASC responses were also compared to the serum responses to see whether any
correlation could be demonstrated. A significant correlation between the fold rise in
serum IgA concentration and the number of IgA ASCs appeared in adults in Study II
(r=0.64, p<0.01) (III; Fig 3), but in Study I no correlation  (Fig 3, r=0.4). The
correlation between the responses was stronger after immunisation with PncD (r=0.75,
p<0.01) than after PncT (r=0.56, p<0.05). The fold rise in serum IgG concentration
showed no correlation with number of IgG ASCs (r=0.3) (I, II). However, in Study II,
the serotype-specific IgG concentrations in serum and in saliva correlated on day 28
(r=0.56, p<0.01) (II: Fig 4);  (r=0.62 after PncD and  r=0.51 after PncT), whereas no
correlation appeared between IgA concentrations in serum and in saliva.
In toddlers, IgA antibodies were rarely detected in serum before immunisation. After
immunisation, a positive correlation existed between the serum IgA antibody
concentration and number of IgA ASCs (r=0.70, p=0.01). The IgA concentrations in
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serum and saliva did not correlate. A weak positive correlation was found between the
fold increase in the serum IgG and the number of IgG ASCs (r=0.60, p=0.01).
Among the AOM patients, all  three (Patients # 1, 2, 3) who had more than 100 IgA-
ASC/106 cells also had an IgA response in NPA and serum (IV: Table). Each of them
also had a serum IgG and/or IgM response. An IgA response in NPA was detected in
three additional patients (# 7, 8, 15), whose IgA ASC responses were low. Furthermore,
IgA in acute or convalescent NPA could be detected in four other children (# 6, 10, 13,
14) with an IgA ASC response. No IgG responses were detected in NPA.
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DISCUSSION
1. Study design
This study consists of four separate studies on pneumococcal PS responses: three phase
I vaccine studies and one study on children with pneumococcal AOM. Each study was
planned separately, and initially, we did not attempt to compare different vaccines.
Instead we were interested in studying the mucosal response to pneumococcal conjugate
vaccines, mainly based on the earlier knowledge that nasopharyngeal carriage of  Hib
was dramatically reduced after Hib-conjugate vaccination (Takala et al.1991, Murphy
et.al. 1993, Mohle-Botani et al. 1993, Takala et al.1993). AOM was chosen to represent
a local, nonsystemic pneumococcal infection in order to study the mucosal response
also in a natural infection.
One of the aims in these studies was to consider how well the measurement of the ASCs
in the peripheral blood (measured with the ELISPOT method), reflects the mucosal
antibody response, measured as salivary antibodies (with EIA). Measuring ASCs is an
indirect way to estimate the mucosal response, since the cells committed to mucosal
sites transiently appear in the peripheral blood when trafficking via the circulation
before homing to their destination. The present study does not provide direct data on the
final distribution of the circulating ASCs into different tissues. Such data could be
obtained by analysing the homing receptors expressed on the surface of the ASCs
(McDermott and Bienenstock 1979, Butcher et al. 1996). However, only a few mucosal
homing receptors are known: those directing the cells to the vascular endothelium of the
gut lamina propria. Receptors directing the cells to respiratory mucosa are still poorly
characterised, and suggested to differ both from the homing receptors of the peripheral
lymph nodes (for serum antibody production), or of the gut mucosa (Abitorabi et al.
1996). Thus, optimal tools to study adhesion molecules of the ASCs committed to the
respiratory mucosa do not exist. In this thesis, the ASC results were compared with the
salivary antibody results, and the results demonstrated that an IgA response in saliva is
related to a high IgA-ASC response.
2. Methodological aspects
In each of the studies, the number of circulating ASCs were counted in the peripheral
blood. In addition, mucosal antibodies were measured in secretions, i.e., in saliva in the
vaccine studies, and in the NPA in the AOM study. Finally, serum antibodies were also
detected in order to estimate the overall immunogenicity of the vaccines in each study
group. For the reasons described above, methods varied slightly between different
studies. Since Study II began, all the assays in our laboratory have been conducted with
the same methods and same reagents. They are therefore comparable, including Studies
II and III. However, the saliva antibody results from the first vaccine study (I) cannot be
directly compared to those in Studies II and III, because at the time Study I was carried
out, the method was still in the process of being improved. Thus, in Study I the salivary
IgA results are not expressed in relation to total IgA in saliva, which has been widely
accepted as a means to compensate for the diurnal and individual variation in the
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protein concentration of secretory samples. In other studies, the salivary IgA results are
given as specific IgA/total IgA (ng/µg). The method for measurement of the ASCs has
remained essentially the same during all these studies. The antisera in the ASC
measurement to detect IgG and IgM differ in Studies I and IV from those used in
Studies II and III. However, the new antisera were first tested, and the ASC results did
not differ from those obtained with the antisera formerly used.
The kinetics of the ASC response after pneumococcal vaccination was analyzed in
Study I. Serotype-specific ASCs were not detected on day 0. Consistent with several
earlier vaccine studies (Kantele et al.1986 and 1990, Tarkowski et al. 1990, Nieminen
et al. 1996), the peak number of ASCs was detected on day 7, thereafter the number of
ASCs decreased, and on day 14 only a few ASCs could be detected. On day 28 or 30
after immunisation, no specific ASCs existed. Occasionally the number of ASCs on day
9 exceeded the number detected on day 7. However, we adopted day 7 as the peak day
to represent the ASC response in our later studies.  The IgM ASC peak is regularly
already seen a few days before the IgA and IgG peak, typically on day 5 (Heilmann et
al.1987, Kantele 1990), as also demonstrated  in Study I. Thus, the study design in II
and III did not allow us to detect the IgM ASC peak. Neither were the days when serum
samples were collected optimal to detect this isotype. Therefore, IgM is not discussed
further in this thesis.
A major problem with saliva samples is the instability of the antibodies; enzymes in the
saliva with degradative activity affect the antibodies in the sample. Therefore special
precautions must be taken in transport and storage. This degradation can be prevented
by addition of enzyme inhibitors and glycerol, and by storing the samples at -70°C
(Butler et al. 1990). In this study, the samples were frozen immediately in dry ice,
stored at -70°C, and thawed only once. Preservatives were not added to the samples, to
avoid additional dilution of the samples, already containing only very low antibody
concentrations. In addition to those sensitivity problems, specificity problems also
existed for salivary EIA, as nonspecific binding was frequently seen. Background plates
were used to control this binding. 
IgG in saliva is suggested to be mostly derived from serum. Consistent with this, a
positive correlation was noted between the IgG response in serum and in saliva, a
finding to be discussed later in more detail. However, a considerable number of
measurements in saliva remained negative for IgG, whatever the IgG concentration in
serum. This could be due to saliva samples too diluted for EIA to detect the IgG
antibodies, resulting from individual and diurnal variation in the salivary protein
concentration (Sörensen et al. 1987) or from degradation of the immunoglobulins by the
proteases in saliva. The first hypothesis is supported by our results, since most of the
saliva results that remained negative for IgG were derived from a small number of
vaccinees, and these vaccinees lacked salivary antibodies to three or four serotypes at
the same time. On the other hand, the total IgA concentration in these saliva samples
with no specific IgG antibodies was no lower than in the remaining samples, indicating
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that these samples were not more diluted. The explanation for this could be that IgG in
saliva may be more prone to unspecific degradation by enzymes in saliva than is the
dimeric S-IgA.
The fold increases in serum antibodies after immunisation are also sometimes difficult
to interpret. Comparison of  individual responses is disturbed by widely varying
antibody concentrations even before immunisation. On the other hand, measurement of
ASCs detects the response at cell level;  no specific ASCs are detected before
immunisation and the number of cells appearing in the blood after immunisation
represents the response: indicating the magnitude of the response as the number of
activated cells. Detecting the number of ASCs in the peripheral blood is therefore a
useful alternative complementing more traditional serological methods for evaluation of
the antibody response On the other hand, ELISPOT is labourious to perform and
requires fresh blood samples for the analysis. It is therefore not useful in phase II
vaccine studies, or in efficacy trials, where large populations are vaccinated, but can be
adapted in phase I vaccine studies to add information on immunogenicity of the
vaccines.
3. Immune responses
3. 1. Responses of vaccinees
Parenterally administered pneumococcal vaccines, the polysaccharide vaccine PncPS,
and the conjugate vaccines PncOMPC, PncD, and PncT were all able to induce mucosal
and serum antibody responses. An ASC response was seen in all vaccinees. In adults,
the responses were higher after the PncD and PncT conjugates than after the PncPS or
PncOMPC. It was initially surprising that in Study I, the ASC and serum antibody
responses in adults were actually lower after the PncOMPC than after PncPS, because
the conjugate was expected to have enhanced immunological properties. This was most
likely a direct consequence of the dose of the PS antigen which was radically different
between the two vaccines: 1 µg/ml of each polysaccharide in the PncOMPC vaccine
and 25 µg/ml in PncPS. Some studies with pneumococcal vaccines have also suggested
that in adults, conjugate vaccines might not be significantly better immunogens than PS
vaccines  (Powers et al. 1996, Eby 1995). However, our later study (II) in adults showed
that the ASC response and the humoral antibody responses were significantly higher
after PncD and PncT conjugates than those seen after PncPS vaccine, indicating that the
immunogenicity of a PS vaccine can be improved by conjugating the PS to a protein
carrier also in adults. This is most likely due to the T-cell help provided that seems to be
beneficial also in adults responding to  PS antigens. This finding supports results from
earlier studies showing a significant difference between PS administered as such and
when conjugated to carrier proteins (Fattom et al. 1990). 
Differences were also seen in the magnitude of the responses between the two conjugate
vaccines PncD and PncT; both the total number of serotype-specific ASCs and the
serum antibody response were higher after immunisation with PncT than after PncD,
whereas salivary antibodies were seen more often after PncD than PncT. The structure
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of PncD and PncT vaccines is quite similar, since they both represent a PS-protein-
conjugate vaccine. However, each of the conjugate vaccines still has its own
characteristics. The polysaccharides in the vaccines can vary in length as well as in the
terminal structure of the saccharide chains. Furthermore, different carrier proteins also
have their own characteristics, and the PS/protein ratio and the coupling of the PS to the
protein differs in each conjugate. These structural characteristics of the PS-protein
conjugates have been shown to have an influence on the amount and the quality of
serum antibody induced by the vaccine (Anderson et al. 1989, Seppälä et al. 1989,
Verheul et al. 1989, van den Wijgert et al. 1991), even though the determinants of the
immunogenicity are not yet understood in detail. It seems likely that the characteristics
of the conjugate vaccines may also have an effect on the induction,  amount, and quality
of the mucosal antibody responses.
The PS antigens are able to induce only poor, if any, antibody responses in young
children. The response to many of the pneumococcal serotypes improves by the age of
2 years, but for some of the serotypes, like 6B, it remains poor much longer, even until
the age of 6 (Mäkelä et al. 1983, Leinonen et al. 1986). However, antibody responses to
PS are seen in young children, because the PS is coupled to a protein carrier to provide
T-cell help. The serum IgG concentrations detected in toddlers after a single dose of
PncD or PncT (III) were comparable in magnitude to those detected in infants after
primary immunisation series (three injections at the ages of 2, 4, and 6 months of age)
(Åhman et al. 1998 and 1999). The booster response in infants was not dependent on
the magnitude of the primary response, indicating that memory function was evoked by
the primary immunisation, even if marked responses were not seen. The ASC responses
seen in toddlers after PncD and PncT, on the other hand, were comparable to those we
reported in adults after the PncPS, a vaccine that is widely used in adult populations to
prevent invasive infections, although it is not able to induce memory. However, the
ability of the conjugate vaccines to generate immunological memory is believed to be
an important factor in protection against invasive infections in children (Eskola et al.
1990). The memory function is likely to play an important role in protection at the
mucosal surfaces, as well.  However, these studies did not evaluate memory function in
the mucosal immune system.
Although  the ASC responses to PncD and PncT were comparable in toddlers to those
in adults after PncPS, the response in toddlers remained lower than in adults after PncD
and PncT. However, salivary IgA antibody responses were seen in toddlers as
frequently as in adults after the same conjugates. Thus the salivary IgA responses were
seen in children as frequently as in adults despite the lower IgA ASC responses in
children. This might suggest that a higher proportion of the IgA ASCs detected in the
peripheral blood is committed to the mucosal sites in children than in adults. Moreover,
only very low serum IgA concentrations were detected  in children, which is consistent
with our knowledge of the late maturation of the serum IgA production in children.
Furthermore, serum IgG concentrations also remained distinctly lower in toddlers than
in adults. Together, these findings suggest that mucosal IgA responses  induced in
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adults and toddlers are comparable, although the overall ASC response in adults is
higher. These findings support those of earlier studies suggesting that the mucosal
compartment of the immune system matures and starts to function earlier in life than the
systemic immune system (Pichichero et al.1981 and 1983).
3. 2. Responses in AOM 
The AOM study (IV) is the first to report a pneumococcal PS-specific ASC response
induced by pneumococcal acute otitis media. The responses measured were specific to
the causative pneumococcal polysaccharide type/group cultured in the MEF, since at
the same time the number of ASCs. measured to other pneumococcal types remained
low. ASCs could be detected in all the children studied, and their number in three of the
children was surprisingly high: 260 to 1100 ASC/106 cells. These values exceeded the
average response detected in the toddlers vaccinated, although more than 1 000
ASC/106 cells were occasionally detected also in children vaccinated with PncD or
PncT. The response in these three children with AOM was high also when compared to
other infections. The number of pathogen-specific ASCs  in urinary tract infection has
been less than 100 ASC/106 cells in most adult patients and even less in children with
pyelonephritis (Kantele et al. 1994 and 1995). The rest of the ASC responses in AOM
children, however, were lower than the average response in vaccinated children. The
induction of immune responses with purified or synthetic antigen preparations is likely
to differ from the situation after contact with live bacteria. The PS antigen lacks T-
dependent properties, but when it is presented on bacteria the number of antigenic
epitopes is higher, and PS antigens conceivably are introduced together with T-
dependent antigens. Furthermore, other factors enhancing or suppressing the response
can be involved, e.g., an ongoing viral infection or mixed bacterial infections that can
induce inflammation and release of various cytokines and thus affect the response in a
way difficult to predict.
The ASC response in children with AOM was clearly age-dependent. High ASC
responses were mostly detected in children 24 months of age or older. This supports the
concept that T-independent polysaccharide antigens are poor immunogens in infants
and young children and that the immunogenicity of the PS antigens is improved by the
age of  2 years. The mucosal IgA-response, however, was induced earlier. None of the
younger children (less than 24 months) had serum antibody responses or an IgG-ASC
response, but six of them had an IgA-ASC response and one a local IgA response in
NPA. Measurable IgA in NPA was further detected in three of the younger children.
This again supports earlier findings that a mucosal IgA response may be induced even
in the first year of life, also to PS antigens that are then unable to mount systemic
responses (Pichichero et al. 1981 and 1983)
3. 3. Serotype-specific responses 
In children with AOM, the highest ASC responses were seen to 19F, the serotype most
commonly causing pneumococcal AOM. Furthermore, this high ASC response was
related to serum and to salivary responses to the same serotype. In vaccinees, the ASC
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responses detected were closely similar to all four serotypes in each vaccine group,
whereas each serum antibody response varied by pneumococcal serotype. The low
serum responses were generally seen after PncPS and PncOMPC and mostly to serotype
6B,  a poor immunogen in several studies (Leinonen et al. 1986, Mäkelä et al. 1989).
After PncD and PncT, the responses to serotype 6B were clearly improved, a finding
also supporting the improved immunogenicity of the conjugate vaccines as compared to
that of PS vaccines. The highest responses, in general, for both serum IgG and salivary
IgA, were to serotype 14 and 19F in adults and to serotype 19F in toddlers. This is in
accordance with earlier findings suggesting that the structure of each PS has a profound
influence on the response, both on magnitude and distribution of the immunoglobulin
classes in the response (van den Dobbelsteen et al. 1992, Korkeila et al. Vaccine, in
press).
4. Isotype distribution of ASC response
After parenteral immunisation with protein vaccines considered to be T-cell-dependent
antigens, the ASC response consists almost exclusively of IgG-producing cells (Lue et
al. 1994, Trollmo et al. 1994). This was seen in the present study in response to the
carrier proteins of the conjugates. Clearly IgG-dominant ASC responses were seen in
adults and toddlers to the protein components of the vaccines. Several studies have
shown that the ASC response to PncPS and other polysaccharide antigens, in contrast
to that of protein antigens, is dominated by IgA-producing cells (Heilman et al. 1986,
Heilman et al. 1987, Heilman et al. 1988, Lue et al.1988, Lue et al. 1990, Tarkowski et
al. 1990). This was also the case in the present study. The IgA/IgG ratio of the ASC
response to a PS that is conjugated to a protein carrier, on the other hand, is altered
towards a pattern typical of  T-cell-dependent antigens (Tarkowski et al. 1990). This
was seen in adults (II) after pneumococcal conjugate vaccines, since both isotypes were
observed in essentially equal numbers; this is in contrast to the response we saw to pure
PS or protein antigens. However, variation in respect to the dominant isotype was
observed between each serotype and different conjugates. In toddlers, on the other
hand, the responses to PS components of the conjugate vaccines were clearly dominated
by IgA-secreting cells. 
The ASC response in children with AOM was always dominated by IgA-ASCs as well,
in accordance with results from earlier studies showing an IgA-dominant ASC response
after other mucosal infections such as gastroenteritis and urinary tract infection
(Kantele et al. 1988 and 1994). The IgA ASC responses detected in AOM children were
within the same range of magnitude as those seen in vaccinated toddlers. IgG ASC
responses after AOM, on the other hand, were detected in only few children, less
frequently than in the vaccinated toddlers. Thus, higher IgG ASC responses were
evident in vaccinated toddlers than in children suffering from pneumococcal  AOM
infection.
As mentioned earlier, the ASC response in adults was higher after PncD and PncT
conjugates, than after PncPS. This difference was more apparent in regard to the IgG
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responses, whereas the numbers of IgA ASCs were more comparable to each other,
indicating that improvement in response to a conjugate vaccine, as compared to a PS
vaccine, mostly concerns the systemic IgG responses. The difference in response
between toddlers and adults after the conjugates was also more evident when the
numbers of IgG ASCs were compared, and less difference was observed between the
numbers of IgA ASCs. This supports the suggestion that although the ability to produce
systemic IgG responses matures with age (and thus better IgG responses are seen in
adults than in children), mucosal IgA responses comparable to those seen in adults can
be induced even at an early age.
In adults some differences were also observed between responses to the two conjugate
vaccines PncD and PncT, not only in the magnitude of responses, but also in the quality
of responses. The number of IgG ASCs was significantly higher after PncT, whereas
equal numbers of  IgA ASCs were detected after PncD and PncT. However, after both
conjugates, the number of IgA ASCs was still higher than in response to pure PS
vaccine. Although the ASC response was not dominated by IgA- or IgG-secreting cells
as clearly as in the response to PS or protein antigens, a clear difference in the IgA/IgG
ratio of the ASC response was obvious between the two conjugate vaccines; IgA cells
dominating in response to PncD, and IgG cells in response to PncT. Furthermore, S-IgA
responses were seen in the saliva more frequently after immunisation with PncD than
with PncT. This occurred despite the equal numbers of IgA ASCs seen after the two
vaccines. Surprisingly, the IgG response in saliva was also higher (although not
significantly) after immunisation with PncD, despite the higher serum IgG
concentration after PncT. Together, these findings suggest that the PncD vaccine is able
to induce better mucosal antibody responses (both IgA and IgG), whereas the PncT
seems to be more efficient in inducing systemic IgG responses. In children, however,
such differences between the two conjugates were not apparent. On the contrary, the
responses were very similar and, as mentioned earlier, the ASC response was always
clearly dominated by IgA-secreting cells. 
5.  Correlation between antibody concentrations and ASC responses
The excellent correlation between serotype-specific IgA and serotype-specific
antibodies associated with secretory component in saliva (Studies I-III) indicates that
the IgA measured in saliva was secretory in nature. The lack of correlation between
serotype-specific IgA in serum and in saliva further supports the fact that the IgA
detected in saliva was locally produced.
In adults, the over twofold increase in specific IgA antibodies in saliva was associated
with an IgA ASC response of more than 100 ASC/106 cells, and in toddlers the fold
increase in IgA concentrations in saliva correlated with the number of IgA ASCs. These
results suggest that a high number of IgA-ASCs detected with ELISPOT is an indicator
of the mucosal IgA response after parenteral pneumococcal vaccination.
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The IgG detected in saliva is mostly suggested to be derived from serum, high serum
IgG concentrations leading to leakage of the antibodies into mucosal secretions
(Brandtzaeg 1971, Korsud et al. 1980, Grönblad 1981). Study II showed that the IgG
concentrations in saliva and serum were positively correlated, in accordance with the
concept of the salivary IgG being from the same origin as is the serum IgG. In toddlers,
salivary IgG was hardly ever detected, which can well be explained by the relatively
low serum PS-specific IgG concentrations detected in toddlers as compared to those in
adults. 
On the other hand, in adults, lower salivary IgG concentrations were induced after PncT
than after PncD, despite the higher serum IgG concentrations after PncT, and
furthermore, in Study I, a salivary IgG response was seen more frequently after
PncOMPC than after PncPS, despite higher serum IgG concentrations after PncPS than
after PncOMPC. These findings suggest that salivary IgG may not be solely a result of
leakage through the mucosal surfaces because of high serum IgG concentration, but that
some of the salivary IgG may be produced locally. Thus, not only secretory IgA, but
also IgG could be induced in secretions somewhat independently of the IgG at systemic
sites. Another explanation could be a higher avidity of salivary IgG induced by
PncOMPC than by PncPS; thus, lower IgG concentrations would be detected in the
antibody assay after PncOMPC. The avidity could be expected to be increased after
conjugated PS as compared to plain PS, as has actually been shown for serum IgG
(Granoff et al. 1995, Anttila et al. 1998). However, it does not explain the differences
between PncD and PncT in adults. One possible explanation is that the permeability of
IgG molecules at mucosal surfaces differs individually or even diurnally in each
individual.
 
One of the main aims of this study was to see how well the number of ASCs would
correlate with the antibody responses, and this was determined also in respect to serum
antibodies. In adults, no significant correlation could be shown between the number of
IgG ASCs and serum IgG concentration. However, the study carried out in toddlers
(III), showed a weak positive correlation. This may have been due to the low
preimmunisation concentrations of pneumococcal IgG seen in toddlers.  In adult
volunteers widely varying concentrations of pneumococcal polysaccharide-specific IgG
antibodies are often detected even before immunisation, which makes analysis of the
correlation between IgG concentration and the number of IgG ASCs impossible. In
toddlers the IgG concentration, as well as the fold increase in IgG concentration,
represents more clearly a new induction of the IgG antibodies and can thus be compared
to the number of IgG ASCs induced by the vaccine.
6. Characteristics of  responses with respect to protection
In this study we have attempted to evaluate the mucosal immune responses, and
therefore  have focussed on IgA. An interesting finding was that the  pneumococcal
conjugate vaccines PncD and PncT were able to induce a salivary IgA antibody
response in toddlers as frequently as was reported for adults in Study II. On the other
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hand, it has been suggested that the reduction in Hib carriage seen after Hib
immunisations is due to high IgG antibody concentrations induced by the vaccines,
leading to leakage of the IgG antibodies to the mucosal surfaces (Robbins et al. 1995
and 1996, Kauppi et al. 1993). However, the serum IgG concentrations in toddlers in
this study remained distinctly lower than in adults. Nevertheless, the serum IgG
concentrations in toddlers were comparable to those reported  in infants after a primary
immunisation series (of three injections) of PncD and PncT (Åhman et al. 1998 and
1999), the same vaccines that are reported to reduce nasopharyngeal carriage of
pneumococcus in infants (Dagan et al. 1996b).
The immune-mediated mechanisms behind the reduced carriage after Hib and
pneumococcal conjugate vaccination still remain contradictory. Both IgA- and IgG-
mediated mucosal immunity have been suggested to prevent colonization. In animal
studies, intranasal administration of human anti-Hib antibodies in an infant rat model
prevented colonization (Kauppi et al. 1993), suggesting that local antibodies play an
important role. However, IgA and IgG were both effective, indicating that both isotypes
prevent colonizations if sufficiently high concentrations are achieved in the
nasopharynx. Furthermore, a high dose of IgG  given intraperitoneally also can prevent
colonization (Kauppi et al. 1993), suggesting that high systemic IgG concentrations
would, indeed, leak into mucosal secretions. Moreover, studies with S. pneumoniae
show that intralitter spread of colonization from one infant rat to another was prevented
by anti-capsular antibodies given subcutaneously (Malley et al. 1998). 
Human studies on passive immuno-prophylaxis have also suggested that systemic,
pneumococcal PS-specific IgG may protect from pneumococcal AOM in high-risk
children, even without stimulation of specific local immunity (Schurin et al. 1993). On
the other hand, the presence of pathogen-specific anti-capsular S-IgA in the middle-ear
fluid even at the onset of acute otitis media seems to be beneficial for the resolution of
the disease (Sloyer et al. 1974, Sloyer et al. 1976, Karjalainen et al.1990). Together,
these findings suggest that capsular polysaccharide specific antibodies of both isotypes,
IgA and IgG, are beneficial in defence against colonization and acute otitis media; the
exact role for the two isotypes still remaining somewhat obscure. Nevertheless, the
improved serum IgG responses to PS antigens achieved with the conjugate vaccines in
the first years of life may well explain the reduced colonization (Robbins et al. 1995
and 1996). However, these studies could not demonstrate IgG responses in salivary
secretions in toddlers. Studies looking more specifically at this issue are still needed to
clarify the role of IgA and IgG in mucosal protection.
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SUMMARY AND CONCLUSIONS
Results of these studies demonstrated mucosal as well as systemic antibody responses
to parenterally administered pneumococcal vaccines PncPS, PncD, and PncT. In these
studies, the mucosal responses were estimated by measurement of salivary antibodies
and by measurement of circulating ASCs in the peripheral blood. An ASC response of
more than 100 IgA-ASC/106 cells was associated with an increase in specific IgA
antibodies in saliva. This good correlation suggests that the ELISPOT method may be
an useful alternative, complementing more traditional serological methods for
evaluation of the mucosal antibody responses to pneumococcal vaccines.
In adults the pneumococcal conjugate vaccines PncD and PncT were able to induce
higher responses than did a polysaccharide vaccine. The characteristics of the response
varied by vaccine; the ASC response to PncPS was dominated by IgA-secreting cells,
whereas the response to conjugate vaccines involved comparable numbers of  IgA- and
IgG-secreting cells. However, differences in the response were also seen between
different conjugates. In toddlers, the ASC responses to PncD and PncT were
comparable to those seen in adults after pneumococcal PS vaccination. Salivary IgA
responses (over a twofold increase in IgA concentration) were detected  in vaccinated
toddlers frequently, at the same incidence as in adult studies with the same vaccines.
Furthermore, pneumococcal polysaccharide-specific responses were induced in children
with AOM; both mucosal and systemic responses were detected. Local immune
responses were, however, seen independently of the systemic responses.
Capsular polysaccharide-specific antibodies, either  IgA or IgG, are beneficial in
defence against mucosal colonization and infection, the exact role for the two isotypes
still remaining somewhat obscure. The high serum IgG concentrations of PS-specific
antibodies that can be achieved with the conjugate vaccines have been suggested to
explain the reduced colonization with encapsulated bacteria in infants and in young
children. The results of these studies showed that the pneumococcal conjugate vaccines
are able to induce high numbers of IgA-secreting cells and secretory IgA in the upper
respiratory mucosa, which may also be important  in mucosal protection. How the
mucosal IgA response correlates with protection still requires further investigation.
Studies looking more specifically at this issue are needed to clarify the exact role of IgA
and IgG in mucosal protection.
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FUTURE CONSIDERATIONS
The aim of this study was to estimate the mucosal immune response induced by
parenteral pneumococcal vaccines. How the response correlates with protection still
remains unanswered. However, pneumococcal conjugate vaccines have already been
shown to reduce nasopharyngeal carriage of the pneumococcal serotypes included in the
vaccines (Dagan et al. 1996, Dagan et al. 1997), indicating mucosal protection. Some
preliminary data also suggest protection against AOM (Black et al. 1999), but specific
proof of the efficacy of the conjugate vaccines in preventing pneumococcal AOM still
remains to be achieved. The Finnish Otitis Media Vaccine Trial  (FinOM) was initiated
in 1995, the target of which is to establish PncCRM vaccine’s protection against
culture-confirmed pneumococcal AOM. Results from this study are expected this year.
 
The exact role of mucosal S-IgA and of serum IgG in reduction of nasopharyngeal
carriage and AOM also needs to be elucidated. Experimental studies have suggested a
role for both S-IgA and IgG in preventing colonization and AOM. Human studies on
passive immuno-prophylaxis have suggested that systemic PS-specific IgG may protect
from pneumococcal AOM (Schurin et al. 1993). On the other hand, the presence of
pathogen-specific anti-capsular S-IgA in the middle-ear fluid has been shown to be
beneficial for resolution of AOM (Sloyer et al. 1974, Sloyer et al. 1976, Karjalainen et
al.1990). The FinOM trial is a prospective study that includes extensive serological
analysis, both of mucosal and systemic antibody responses. After the results from these
studies are available, we can expect to have better estimates of serological correlations
with protection against AOM.
Because mucosal protection can be expected to be at least partially S-IgA-mediated, the
mucosal administration route of antigens is being intensively studied and can be
expected to provide new strategies against microbes invading the body through mucosal
surfaces. Furthermore, pneumococcal proteins: PspA,  PsaA, and pneumolysin, and
their ability to induce antibody-mediated protection, is currently a field of interest. Both
mucosal and systemic protection are being evaluated, and mucosal administration of
these proteins has been intensively studied. Animal studies on mucosal vaccination
have also suggested that mucosal administration can sufficiently induce biologically
active serum IgG responses (Flanagan et al. 1997, Seong et al. 1999, Jakobsen et al.
1999). If  the same can be accomplished in human beings, systemic infections that do
not involve invasion through mucosal surfaces (e.g., tetanus) could also be prevented by
mucosal vaccination; some preliminary data on mucosal immunogenicity in humans
already exists (Aggerbeck et al. 1997). Significant effort is being invested in research
on mucosal vaccines, and the feasibility of vaccination via mucosal routes should be
appraised in few years. An optimistic view for the future would be a single-dose
vaccine given to small infants via the mucosal route.
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